INDUSTRY EXPERT SESSIONS

Friday, March 1, 2019

These unique sessions provide exhibiting companies the opportunity to:

- Present new research findings on products
- Detail products
- Conduct demonstrations
- Highlight new products

These sessions are solely promotional and are not eligible for continuing medical education credit.

Location: Exhibit Hall

11:00 AM - 11:45 AM
Hosted by: Boehringer Ingelheim Pharmaceuticals, Inc.
Title: Pustular Psoriasis: Pathogenesis and Therapeutic Options (Current and Future)
Description:
Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) are variants of psoriasis, although both diseases are genetically and/or clinically distinct. Uncontrolled activation of the IL-36 pathway can drive inflammatory pustular skin diseases. Targeting this pathway may prove a feasible approach to treating these subtypes of pustular psoriasis.

12:15 PM - 1:00 PM
Hosted by: Celgene Corporation
Title: Moving Beyond Topicals: Perspectives on Systemic Treatment for Psoriasis
Description:
This is an unbranded program in which Dr. Paul Yamauchi will be discussing the unmet needs for psoriasis patients, challenges of topical-only treatment and considerations for transitioning patients from a topical to a systemic therapy.

1:30 PM - 2:15 PM
Hosted by: Pfizer, Inc.
Title: An Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 Years and Older
Description:
Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mild-to-moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option.

2:45 PM – 3:30 PM
Hosted by: Novartis Pharmaceuticals Corporation
INDUSTRY EXPERT SESSIONS

Saturday, March 2, 2019

These unique sessions provide exhibiting companies the opportunity to:

- Present new research findings on products
- Detail products
- Conduct demonstrations
- Highlight new products

These sessions are solely promotional and are not eligible for continuing medical education credit.

**Location: Exhibit Hall**

**11:00 AM - 11:45 AM**

**Hosted by:** Novartis Pharmaceuticals Corporation

**Title:** Are Your Topical Patients Systemic-Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis

**Description:**
Dr. Robert Greenberg will be presenting a current oral, non-biologic treatment option in moderate to severe plaque psoriasis.

**12:15 PM - 1:00 PM**

**Hosted by:** Celgene Corporation

**Title:** A First-line Biologic with Head-to-Head Data vs Adalimumab vs Secukinumab

**Description:**
Review TREMFYA® clinical efficacy and safety data from the VOYAGE 1 and VOYAGE 2 pivotal trial and review TREMFYA® clinical efficacy and safety data from the ECLIPSE trial. Presented by Jennifer Soung, MD and Steven R. Feldman, MD, PhD

**1:30 PM - 2:15 PM**

**Hosted by:** Janssen Biotech, Inc.

**Title:** A First-line Biologic with Head-to-Head Data vs Adalimumab vs Secukinumab

**Description:**
Review TREMFYA® clinical efficacy and safety data from the VOYAGE 1 and VOYAGE 2 pivotal trial and review TREMFYA® clinical efficacy and safety data from the ECLIPSE trial. Presented by Jennifer Soung, MD and Steven R. Feldman, MD, PhD

**2:45 PM – 3:30 PM**

**Hosted by:** Dermira, Inc.

**Title:** QBREXZA Industry Expert Session
INDUSTRY EXPERT SESSIONS

Sunday, March 3, 2019

These unique sessions provide exhibiting companies the opportunity to:

- Present new research findings on products
- Detail products
- Conduct demonstrations
- Highlight new products

These sessions are solely promotional and are not eligible for continuing medical education credit.

Location: Exhibit Hall

11:00 AM - 11:45 AM
Hosted by: Regeneron and Sanofi Genzyme
Title: DUPIXENT® (dupilumab): Approved for Two Indications
Description:
DUPIXENT is approved by the FDA. Come learn about clinical efficacy, safety information, MOA, and dosing and administration, and how DUPIXENT may help your patients.

12:15 PM - 1:00 PM
Hosted by: UCB, Inc.
Title: CIMZIA® (certolizumab pegol) for the Management of Psoriatic Disease

1:30 PM - 2:15 PM
Hosted by: Leo Pharma, Inc.
Title: Advances in Atopic Dermatitis – Refocusing the Lens
Description:
This session will uncover recent global research in AD that exposes how heterogeneous the disease is, by focusing below the skin surface. Understanding this heterogenicity, along with the complex TH2 pathways involved, may help focus advancements in AD science.